HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $10 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and maintains $10 price target.
HC Wainwright & Co. Reiterates Buy on Indaptus Therapeutics, Maintains $15 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Indaptus Therapeutics (NASDAQ:INDP) with a Buy and maintains $15 price target.
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $16 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $16 price target.
Ladenburg Thalmann Reiterates Buy on Kiora Pharmaceuticals, Maintains $119 Price Target
Ladenburg Thalmann analyst Matthew Kaplan reiterates Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and maintains $119 price target.
Wedbush Reiterates Outperform on Microsoft, Maintains $280 Price Target
Wedbush analyst Daniel Ives reiterates Microsoft (NASDAQ:MSFT) with a Outperform and maintains $280 price target.
SVB Leerink Reiterates Underperform on Incyte, Maintains $63 Price Target
SVB Leerink analyst Andrew Berens reiterates Incyte (NASDAQ:INCY) with a Underperform and maintains $63 price target.
Telsey Advisory Group Reiterates Outperform on VF, Maintains $36 Price Target
Telsey Advisory Group analyst Dana Telsey reiterates VF (NYSE:VFC) with a Outperform and maintains $36 price target.
SVB Leerink Reiterates Outperform on Deciphera Pharmaceuticals, Maintains $30 Price Target
SVB Leerink analyst Andrew Berens reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and maintains $30 price target.
This Analyst Remains Bullish On BellRing Brands As Setup For FY23 Is ‘Strong’
Needham analyst Matt McGinley reiterated a Buy rating on the shares of BellRing Brands Inc (NYSE:BRBR) with a price target of $32.…
Varonis Has Ample Upside Backed By SaaS Service And DataAdvantage Cloud, Analyst Says Post Q4
JMP Securities analyst Erik Suppiger reiterated a Market Outperform on Varonis Systems, Inc (NASDAQ:VRNS) and a $63 price target. The 4Q22 results…